| Route | Form | Dose | Brand name | Availability [b] |
|---|---|---|---|---|
| Oral | Capsule | 100, 200, 300 mg | Prometrium [c] | Widespread |
| Tablet ( SR) | 200, 300, 400 mg | Dubagest SR [c] | India | |
| Sublingual | Tablet | 10, 25, 50, 100 mg | Luteina [c] | Europe [d] |
| Transdermal | Gel [e] | 1% (25 mg) | Progestogel | Europe |
| Vaginal | Capsule | 100, 200 mg | Utrogestan | Widespread |
| Tablet | 100 mg | Endometrin [c] | Widespread | |
| Gel | 4, 8% (45, 90 mg) | Crinone [c] | Widespread | |
| Suppository | 200, 400 mg | Cyclogest | Europe | |
| Ring | 10 mg/day [f] | Fertiring [c] | South America [g] | |
| Rectal | Suppository | 200, 400 mg | Cyclogest | Europe |
| Uterine | IUD | 38 mg | Progestasert | Discontinued |
|
Intramuscular injection |
Oil solution | 2, 5, 10, 20, 25, 50, 100 mg/mL |
Proluton [c] | Widespread |
| Aq. susp. | 12.5, 30, 100 mg/mL | Agolutin [c] | Europe [h] | |
| Emulsion | 5, 10, 25 mg/mL | Di-Pro-Emulsion | Discontinued | |
| Microsph. | 20, 100 mg/mL | ProSphere [c] | Mexico | |
| Subcutaneous | Aq. soln. ( inj.) | 25 mg/vial | Prolutex | Europe |
| Implant | 50, 100 mg | Proluton [c] | Discontinued | |
| Intravenous | Aq. soln. ( inj.) | 20 mg/mL | Primolut | Discontinued |
Sources and footnotes:
| ||||
Template documentationSee also
- Progesterone (medication) § Available forms
- Pharmacokinetics of progesterone § Routes of administration
- Template:Available forms of estradiol
- Template:Available forms of testosterone
References
- ^ "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 26 July 2018.
- ^ Engel J, Kleemann A, Kutscher B, Reichert D (14 May 2014). Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs. Thieme. pp. 1145–. ISBN 978-3-13-179275-4.
- ^ Becker KL (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 2168–. ISBN 978-0-7817-1750-2.
- ^ Anita MV, Jain S, Goel N (31 July 2018). Use of Progestogens in Clinical Practice of Obstetrics and Gynecology. JP Medical Ltd. pp. 4–. ISBN 978-93-5270-218-3.
- ^ Sauer MV (1 March 2013). Principles of Oocyte and Embryo Donation. Springer Science & Business Media. pp. 7, 117–118. ISBN 978-1-4471-2392-7.
- ^ Elder K, Dale B (2 December 2010). In-Vitro Fertilization. Cambridge University Press. pp. 26–. ISBN 978-1-139-49285-0.
- ^ "PROSPHERE CARNOT". Archived from the original on 2019-12-30.
- ^ Heinrich Kahr (8 March 2013). Konservative Therapie der Frauenkrankheiten: Anzeigen, Grenzen und Methoden Einschliesslich der Rezeptur. Springer-Verlag. pp. 21–. ISBN 978-3-7091-5694-0.
- ^ Basic Sex Hormone Therapy. Schering A.G. 1962. p. 96.
-
^
Current Medicine and Drugs. 1962. p. 40.
Primolut Intravenous (Schering A.G. Berlin)
- ^ Haleem S, Khan MI (March 2015). "Changing Indian Market Trends of NMP: A Review" (PDF). International Journal of Pharma Research & Review. 4 (3): 28–30. ISSN 2278-6074. S2CID 74224514.
| Route | Form | Dose | Brand name | Availability [b] |
|---|---|---|---|---|
| Oral | Capsule | 100, 200, 300 mg | Prometrium [c] | Widespread |
| Tablet ( SR) | 200, 300, 400 mg | Dubagest SR [c] | India | |
| Sublingual | Tablet | 10, 25, 50, 100 mg | Luteina [c] | Europe [d] |
| Transdermal | Gel [e] | 1% (25 mg) | Progestogel | Europe |
| Vaginal | Capsule | 100, 200 mg | Utrogestan | Widespread |
| Tablet | 100 mg | Endometrin [c] | Widespread | |
| Gel | 4, 8% (45, 90 mg) | Crinone [c] | Widespread | |
| Suppository | 200, 400 mg | Cyclogest | Europe | |
| Ring | 10 mg/day [f] | Fertiring [c] | South America [g] | |
| Rectal | Suppository | 200, 400 mg | Cyclogest | Europe |
| Uterine | IUD | 38 mg | Progestasert | Discontinued |
|
Intramuscular injection |
Oil solution | 2, 5, 10, 20, 25, 50, 100 mg/mL |
Proluton [c] | Widespread |
| Aq. susp. | 12.5, 30, 100 mg/mL | Agolutin [c] | Europe [h] | |
| Emulsion | 5, 10, 25 mg/mL | Di-Pro-Emulsion | Discontinued | |
| Microsph. | 20, 100 mg/mL | ProSphere [c] | Mexico | |
| Subcutaneous | Aq. soln. ( inj.) | 25 mg/vial | Prolutex | Europe |
| Implant | 50, 100 mg | Proluton [c] | Discontinued | |
| Intravenous | Aq. soln. ( inj.) | 20 mg/mL | Primolut | Discontinued |
Sources and footnotes:
| ||||
Template documentationSee also
- Progesterone (medication) § Available forms
- Pharmacokinetics of progesterone § Routes of administration
- Template:Available forms of estradiol
- Template:Available forms of testosterone
References
- ^ "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 26 July 2018.
- ^ Engel J, Kleemann A, Kutscher B, Reichert D (14 May 2014). Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs. Thieme. pp. 1145–. ISBN 978-3-13-179275-4.
- ^ Becker KL (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 2168–. ISBN 978-0-7817-1750-2.
- ^ Anita MV, Jain S, Goel N (31 July 2018). Use of Progestogens in Clinical Practice of Obstetrics and Gynecology. JP Medical Ltd. pp. 4–. ISBN 978-93-5270-218-3.
- ^ Sauer MV (1 March 2013). Principles of Oocyte and Embryo Donation. Springer Science & Business Media. pp. 7, 117–118. ISBN 978-1-4471-2392-7.
- ^ Elder K, Dale B (2 December 2010). In-Vitro Fertilization. Cambridge University Press. pp. 26–. ISBN 978-1-139-49285-0.
- ^ "PROSPHERE CARNOT". Archived from the original on 2019-12-30.
- ^ Heinrich Kahr (8 March 2013). Konservative Therapie der Frauenkrankheiten: Anzeigen, Grenzen und Methoden Einschliesslich der Rezeptur. Springer-Verlag. pp. 21–. ISBN 978-3-7091-5694-0.
- ^ Basic Sex Hormone Therapy. Schering A.G. 1962. p. 96.
-
^
Current Medicine and Drugs. 1962. p. 40.
Primolut Intravenous (Schering A.G. Berlin)
- ^ Haleem S, Khan MI (March 2015). "Changing Indian Market Trends of NMP: A Review" (PDF). International Journal of Pharma Research & Review. 4 (3): 28–30. ISSN 2278-6074. S2CID 74224514.